24/7 Market News Snapshot 08 May, 2025 – Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

May 8, 2025

DENVER, Colo., 08 May, 2025 (www.247marketnews.com) – (NASDAQ:CRVS) are discussed in this article.
Corvus Pharmaceuticals, Inc. has experienced significant market momentum, with its stock price jumping from an opening of $3.19 to $5.743, representing an impressive increase of 79.47%. This surge is driven by heightened investor interest marked by a trading volume of 2.19 million shares. The close of the previous session at $3.20 signifies a notable turnaround, drawing attention to the stock’s volatility and creating potential for further appreciation.

In addition to its notable stock performance, Corvus Pharmaceuticals is excited to share interim data from its Phase 1 clinical trial investigating soquelitinib, an innovative treatment for moderate to severe atopic dermatitis. The upcoming announcement, scheduled for presentation at the Society for Investigative Dermatology 2025 Annual Meeting, indicates a promising safety and efficacy profile, particularly in the third cohort of trial participants receiving a 200 mg dose twice daily.

Results indicated a remarkable 71.1% reduction in mean Eczema Area and Severity Index (EASI) scores at the 28-day mark for patients in this cohort, compared to a mere 42.1% reduction observed in the placebo group. These findings highlight soquelitinib’s unique mechanism as a selective ITK inhibitor, which plays a critical role in diminishing inflammatory cytokines associated with atopic dermatitis.

Dr. Richard A. Miller, the co-founder and CEO of Corvus Pharmaceuticals, expressed enthusiasm regarding the trial outcomes, stating, “These results bolster our belief in soquelitinib’s capabilities as an effective treatment option.” He further noted plans to enhance the ongoing trial by adding another cohort and extending the treatment period to refine the assessment of its efficacy.

Corvus Pharmaceuticals is committed to advancing the development of soquelitinib, with a Phase 2 trial anticipated to begin by year-end, aiming to transform treatment options for patients suffering from immune-mediated diseases. Data from this important study will be showcased by Dr. Albert S. Chiou during an oral session and a poster presentation at the upcoming Annual Meeting.

Related news for (CRVS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.